D4CG News - Page 2 of 3 - Data for the Common Good

PCDC named Champion of Open Science by White House

We are extremely honored to share that the Pediatric Cancer Data Commons has been named one of five Champions of Open Science by the White House Office of Science and Technology Policy (OSTP). These awards highlight efforts that tackle problems by broadening access to research so that everyone can benefit from science and technology. The PCDC and the other four winners “exemplify what’s possible with an open, equitable, and secure research enterprise.”

The Gray Foundation invests in collaboration seeking diabetes treatments

Published in UChicago Medicine Giving | February 15, 2024

Science Spotlight: INSTRuCT

Welcome to the Science Spotlight, where we highlight the scientific advancements made possible by our consortia and data commons.

In this Science Spotlight, INSTRuCT profiles several recent consensus papers in which they offer guidelines for imaging and molecular testing that could be used to inform future clinical trial protocols for soft-tissue sarcoma.

Webinar: “Making connections: communities, tools, and new horizons for data-driven discovery”

We’re pleased to share the video from our public webinar held October 25, 2023.

Science Spotlight: INRG

Welcome to the Science Spotlight, where we highlight the scientific advancements made possible by our consortia and data commons.

In this Science Spotlight, INRG profiles two recent neuroblastoma publications, how they used INRG data from the PCDC, and how they might impact future research and patient care.

PCDC in the media, Fall 2022

This Childhood Cancer Awareness Month, we’ve been honored to have the Pediatric Cancer Data Commons featured in news broadcasts, interviews, articles, and podcasts. Read, watch, and listen here!

Disparities in Childhood Cancer: Now Is the Time

Conversations for the Common Good series

Carlos Rodriguez-Galindo, MD, director of St. Jude Global and chair of the Department of Global Pediatric Medicine, reviews the current estimates of the global burden of childhood cancer and disparities in access to quality care, and discusses current initiatives to address them.

Webinar: “Connect, Share, Discover: How Democratizing Data is Changing Research.”

We’re pleased to share the video from our public webinar held May 18, 2022.

Harnessing Collaborative Frameworks Across Consortia as Paired with Emerging National Data-driven Infrastructure to Advance Clinical Translation for Children with Brain Tumors

Conversations for the Common Good welcomes Adam Resnick, PhD, Director of the Center for Data Driven Discovery in Biomedicine at Children’s Hospital of Philadelphia and Principal Investigator of the Gabriella Miller Kids First Data Resource Center. Pediatric brain tumors are the leading cause of disease-related death in children. To address the unmet need for large-scale datasets that can inform new research and therapeutic development across the heterogeneous disease landscape of pediatric brain tumors, multi-institutional national/international consortia like the Children’s Brain Tumor Network have undertaken the centralized integration of samples and associated clinical/phenotypic patient data on behalf of a collaborative discovery research framework. Over the past five years, such efforts have further informed the development of the Gabriella Miller Kids First Data Resource, an NIH-supported, cloud-based platform focused on pediatric cross-disease analyses, as well as further contributed to NCI-sponsored data generation efforts supported by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and more recently the Childhood Cancer Data Initiative (CCDI). Together, these large-scale data and platform resources are newly poised to advance and inform an emerging pediatric data commons landscape on behalf of accelerated, collaborative discovery and translational clinical impact.

Putting Children First: New Models for Pediatric Oncology Drug Development

Sam Blackman, MD, PhD, co-founder and Chief Medical Officer of Day One Biopharmaceuticals, discusses how pediatric oncology drug development can change for the better. Dr. Blackman, who has led the early clinical development of more than 10 novel cancer therapeutics, describes the challenges that have limited the pace of development of new therapeutics for pediatric cancer, new business models that may be capable of changing this dynamic, and how the pediatric oncology ecosystem can work together to enable success.